Translate Bio, Inc.
telesisbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2021 10-Q, filed Aug 5, 2021. Its latest SEC filing is a 15-12B from Sep 24, 2021.
10-Q for Q2 FY2021, filed Aug 5, 2021
The sections below describe the company as of the FY2020 annual report.
What Did They Do?
Develops mRNA medicines for pulmonary diseases and mRNA vaccines for infectious diseases with Sanofi.
10-K for FY2020, filed Mar 1, 2021
Who Were Their Customers?
Sanofi works with the company on infectious-disease vaccines. Translate Bio planned to commercialize its other candidates through its own specialty sales force in the United States and potentially Europe, and through third parties in some other markets.
10-K for FY2020, filed Mar 1, 2021
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2021, filed Aug 5, 2021
$17.1MView ↗
- ▲ Now profitable
- vs −$36.3M in Q2 FY2020
-
Sep 14, 2021
Sanofi completed its acquisition of Translate Bio
Translate Bio became an indirect wholly owned subsidiary of Sanofi, and the company requested delisting of its shares from Nasdaq.
Sources
8-K, filed Sep 14, 2021
Following the completion of the Offer, on September 14, 2021, pursuant to the terms of the Merger Agreement and in accordance with Section…View ↗
Who Did They Compete With?
Competes with Novartis, GlaxoSmithKline, Moderna, CureVac, BioNTech, Ethris, Arcturus Therapeutics Holdings, eTheRNA immunotherapies, ReCode Therapeutics, Strand Therapeutics, GreenLight BioSciences, Kernal Biologics, Genevant Sciences, Vertex, AbbVie, Eloxx Pharmaceuticals, Proteostasis Therapeutics, and CRISPR Therapeutics
10-K for FY2020, filed Mar 1, 2021Companies with mRNA platform capabilities include: Novartis AG, GlaxoSmithKline plc, Moderna, Inc., CureVac AG, BioNTech AG, Ethris GmbH…View ↗
Loading...
